Two adalimumab biosimilars (Amjevita and Imraldi) worked as well for moderate to severe psoriasis as the original brand-name ...

Overall, the study’s findings support the use of Amjevita and Imraldi as equally effective alternatives to Humira in the real ...

That's not necessarily what the data say, but in the clinic, I feel like adalimumab is still a really great initial option." For patients with skin-only psoriasis and no insurance issues ...

Symptoms can include itching, pain, or swelling. Humira can also cause new or worsen psoriasis, a condition Humira is approved to treat. Psoriasis is a skin condition that causes symptoms such as ...

Biocon’s ustekinumab biosimilar matched reference ustekinumab in efficacy and safety, while an adalimumab biosimilar proved ...

Humira’s success is down to its incredible versatility – an anti-TNF drug, it is approved in a range of inflammatory diseases, including rheumatoid arthritis, plaque psoriasis and Crohn’s ...

with the latter two rivalling Humira in indications such as rheumatoid arthritis and psoriasis. Kavya Gopal, head of specialty at Sandoz UK, said: “Biosimilars offer the NHS the potential to ...

Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to Stelara, J&J's blockbuster psoriasis treatment.

Opens in a new tab or window Uncertainties remain about the real-world benefit of adalimumab biosimilars for psoriasis, limiting their widespread adoption. This analysis involving patients in the ...